**Core Concept**
The bcr-abl gene fusion occurs due to a reciprocal translocation between chromosomes 9 and 22, resulting in the formation of the Philadelphia chromosome. This genetic abnormality leads to the creation of a chimeric tyrosine kinase enzyme, which plays a crucial role in the pathogenesis of certain hematological malignancies.

**Why the Correct Answer is Right**
The t(9;22) translocation involves the juxtaposition of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. This fusion event leads to the creation of a constitutively active tyrosine kinase enzyme, which promotes cell proliferation and survival. The resulting bcr-abl fusion protein has a higher tyrosine kinase activity compared to the wild-type ABL1 protein, contributing to the development of chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the t(8;14) translocation is characteristic of Burkitt lymphoma, where the MYC gene on chromosome 8 is juxtaposed with the IGH gene on chromosome 14.
**Option B:** This option is incorrect because the t(11;14) translocation is associated with mantle cell lymphoma, where the CCND1 gene on chromosome 11 is juxtaposed with the IGH gene on chromosome 14.
**Option C:** This option is incorrect because the t(15;17) translocation is characteristic of acute promyelocytic leukemia (APL), where the PML gene on chromosome 15 is fused with the RARα gene on chromosome 17.

**Clinical Pearl / High-Yield Fact**
The bcr-abl fusion protein is a potent inhibitor of apoptosis, contributing to the clonal expansion of leukemic cells. The development of tyrosine kinase inhibitors (TKIs) targeting the bcr-abl fusion protein has revolutionized the treatment of CML, offering improved survival outcomes for patients with this disease.

**Correct Answer: C. Acute Lymphoblastic Leukemia (ALL)**